Aclarion Inc. (ACON)
NASDAQ (CM) NASDAQ (CM) Primary 
XFRA Summary
Aclarion, Inc. (ACON) Reports Q2 Loss, Lags Revenue Estimates
Aclarion, Inc. (ACON) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to a loss of $2.75 per share a year ago.
Aclarion (ACON) Upgraded to Buy: Here's Why
Aclarion (ACON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aclarion, Inc. (ACON) Reports Q1 Loss, Misses Revenue Estimates
Aclarion, Inc. (ACON) came out with a quarterly loss of $1.34 per share versus the Zacks Consensus Estimate of a loss of $1.55. This compares to a loss of $9.32 per share a year ago.
Aclarion Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| ABB Alexander Bjornager Bonde Danske Bank A/S | 1 | $11 | $2.56 | -$8.44 | -76.73% |
| BO Brian Oliveira Clear Street Group Inc. | 103 | $311.35 | $264.19 | -$47.16 | -15.15% |
 Hui Fai Tam Caitong International Asset Management Co. Ltd. | 4 | $12 | $10.16 | -$1.84 | -15.33% |
Aclarion Inc. (ACON) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Aclarion Inc. ever had a stock split?
Aclarion Inc. Profile
| Health Care Technology Industry | Healthcare Sector | Brent Ness CEO | NASDAQ (CM) Exchange | 655187409 CUSIP |
| US Country | 11 Employees | - Last Dividend | 28 Mar 2025 Last Split | - IPO Date |
Overview
Aclarion, Inc. is a pioneering healthcare technology company based in the United States, focusing on leveraging Magnetic Resonance Spectroscopy (MRS) technology to advance the medical field. MRS is a non-invasive diagnostic technique that provides detailed information about the chemical composition of the body, which is crucial for diagnosing various conditions. Initially founded as Nocimed, Inc. in 2008, the company underwent a significant rebranding, adopting the name Aclarion, Inc. in December 2021. With its headquarters located in Broomfield, Colorado, Aclarion is committed to developing innovative software solutions designed to enhance clinical decision-making processes, particularly in the assessment and management of degenerative pain conditions.
Products and Services
The company has developed the NOCISCAN Post-Processor suite of software applications, which includes two main products:
- NOCICALC: This software component is crucial for processing the raw, unprocessed MRS exam data. Once it receives this data, NOCICALC post-processes it into final spectra. This process is fundamental as it transforms raw MRS data into a form that can be interpreted and analyzed. Additionally, NOCICALC performs various analyses to identify degenerative pain biomarkers, which are critical for diagnosing and treating pain related to degenerative conditions. Through its sophisticated algorithms, NOCICALC supports healthcare professionals in enhancing their understanding of a patient's condition, enabling more accurate diagnoses and personalized treatment planning.
- NOCIGRAM: Serving as a clinical decision support software, NOCIGRAM complements the data processing capabilities of NOCICALC by offering actionable insights and recommendations. This software is instrumental in interpreting the processed MRS data, providing clinicians with a comprehensive evaluation of the patient's condition. NOCIGRAM aims to simplify complex data, making it accessible and understandable for medical professionals, which, in turn, assists in making informed and evidence-based clinical decisions. It represents a critical step towards integrating advanced diagnostic technologies into everyday clinical practice, facilitating improved patient outcomes.
